These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17668043)

  • 1. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
    Stoddart CA; Bales CA; Bare JC; Chkhenkeli G; Galkina SA; Kinkade AN; Moreno ME; Rivera JM; Ronquillo RE; Sloan B; Black PL
    PLoS One; 2007 Aug; 2(7):e655. PubMed ID: 17668043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
    Pettoello-Mantovani M; Kollmann TR; Raker C; Kim A; Yurasov S; Tudor R; Wiltshire H; Goldstein H
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1880-7. PubMed ID: 9303378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.
    Stoddart CA; Moreno ME; Linquist-Stepps VD; Bare C; Bogan MR; Gobbi A; Buckheit RW; Bedard J; Rando RF; McCune JM
    Antimicrob Agents Chemother; 2000 Mar; 44(3):783-6. PubMed ID: 10681360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1.
    Kollmann TR; Pettoello-Mantovani M; Zhuang X; Kim A; Hachamovitch M; Smarnworawong P; Rubinstein A; Goldstein H
    J Exp Med; 1994 Feb; 179(2):513-22. PubMed ID: 8294863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
    Stoddart CA; Joshi P; Sloan B; Bare JC; Smith PC; Allaway GP; Wild CT; Martin DE
    PLoS One; 2007 Nov; 2(11):e1251. PubMed ID: 18043758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues.
    Pettoello-Mantovani M; Kollmann TR; Katopodis NF; Raker C; Kim A; Yurasov S; Wiltshire H; Goldstein H
    J Infect Dis; 1998 Feb; 177(2):337-46. PubMed ID: 9466519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model.
    Honeycutt JB; Wahl A; Archin N; Choudhary S; Margolis D; Garcia JV
    Retrovirology; 2013 Oct; 10():121. PubMed ID: 24156277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model.
    Taggart BR; Harrington P; Hollingshead M
    Antiviral Res; 2004 Jul; 63(1):1-6. PubMed ID: 15196814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320.
    Stoddart CA; Rabin L; Hincenbergs M; Moreno M; Linquist-Stepps V; Leeds JM; Truong LA; Wyatt JR; Ecker DJ; McCune JM
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2113-5. PubMed ID: 9687417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms.
    Kovalev G; Duus K; Wang L; Lee R; Bonyhadi M; Ho D; McCune JM; Kaneshima H; Su L
    J Immunol; 1999 Jun; 162(12):7555-62. PubMed ID: 10358212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice.
    Scoggins RM; Taylor JR; Patrie J; van't Wout AB; Schuitemaker H; Camerini D
    J Virol; 2000 Apr; 74(7):3205-16. PubMed ID: 10708437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
    Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells.
    Wang EJ; Pettoello-Mantovani M; Anderson CM; Osiecki K; Moskowitz D; Goldstein H
    J Infect Dis; 2002 Nov; 186(10):1412-21. PubMed ID: 12404156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
    Rabin L; Hincenbergs M; Moreno MB; Warren S; Linquist V; Datema R; Charpiot B; Seifert J; Kaneshima H; McCune JM
    Antimicrob Agents Chemother; 1996 Mar; 40(3):755-62. PubMed ID: 8851606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HIV-1 determinants for replication in vivo.
    Su L; Kaneshima H; Bonyhadi ML; Lee R; Auten J; Wolf A; Du B; Rabin L; Hahn BH; Terwilliger E; Mccune JM
    Virology; 1997 Jan; 227(1):45-52. PubMed ID: 9007057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections.
    Kern ER; Rybak RJ; Hartline CB; Bidanset DJ
    Antivir Chem Chemother; 2001; 12 Suppl 1():149-56. PubMed ID: 11594682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model.
    Banda NK; Akkina RK; Terrell K; Shpall EJ; Tomczak J; Campain J; Claman H; Cagle L; Harrison GS
    J Hematother; 1998 Aug; 7(4):319-31. PubMed ID: 9735863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice.
    Kollmann TR; Kim A; Pettoello-Mantovani M; Hachamovitch M; Rubinstein A; Goldstein MM; Goldstein H
    J Immunol; 1995 Jan; 154(2):907-21. PubMed ID: 7814892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses.
    Okuma K; Tanaka R; Ogura T; Ito M; Kumakura S; Yanaka M; Nishizawa M; Sugiura W; Yamamoto N; Tanaka Y
    J Infect Dis; 2008 Jan; 197(1):134-41. PubMed ID: 18171296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the signal transducer and activator of transcription 1 signaling pathway in thymocytes from HIV-1-infected human thymus.
    Miller ED; Smith JA; Lichtinger M; Wang L; Su L
    AIDS; 2003 Jun; 17(9):1269-77. PubMed ID: 12799548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.